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Abstract
The immunologic consequences of prolonged infusions of rIL-2
in doses that produce physiologic serum concentrations of this
cytokine were investigated. rIL-2 in doses of 0.54.0 x 106
U/im2 per d (3.3-40 ,gg/m2 per d) was administered by continu-
ous intravenous infusion for 90 consecutive days to patients
with advanced cancer. IL-2 concentrations (25±25 and 77±64
pM, respectively) that selectively saturate high-affinity IL-2
receptors (IL-2R) were achieved in the serum of patients re-
ceiving rIL-2 infusions of 10 Agg/m2 per d and 30 gg/m2 per d.
A gradual, progressive expansion of natural killer (NK) cells
was seen in the peripheral blood of these patients with no evi-
dence ofa plateau effect during the 3 mo of therapy. A preferen-
tial expansion of CD56"'b"t NK cells was consistently evident.
NK cytotoxicity against tumor targets was only slightly en-
hanced at these dose levels. However, brief incubation of these
expanded NK cells with IL-2 in vitro induced potent lysis of
NK-sensitive, NK-resistant, and antibody-coated targets. Infu-
sions of rIL-2 at 40 ,g/m2 per d produced serum IL-2 levels
(345±381 pM) sufficient to engage intermediate affinity IL-2R
p75, which is constitutively expressed by human NK cells. This
did not result in greater NK cell expansion compared to the
lower dose levels, but did produce in vivo activation of NK
cytotoxicity, as evidenced by lysis of NK-resistant targets.
There was no consistent change in the numbers of CD56 -
CD3+ T cells, CD56+ CD3+ MHC-unrestricted T cells, or B
cells during infusions of rIL-2 at any of the dosages used. This
study demonstrates that prolonged infusions of rIL-2 in doses
that saturate only high affinity IL-2R can selectively expand
human NK cells for an extended period of time with only mini-
mal toxicity. Further activation of NK cytolytic activity can
also be achieved in vivo, but it requires concentrations of IL-2
that bind intermediate affinity IL-2R p75. Clinical trials are
underway attempting to exploit the differing effects of various
concentrations of IL-2 on human NK cells in vivo. (J. Clin.
Invest. 1993. 91:123-132.) Key words: IL-2 * natural killer
cells - immunotherapy - IL-2 receptor * cytotoxicity
Introduction
IL-2 plays a central role in the vertebrate immune response
( 1 ). Produced by T lymphocytes activated through exposure to
Address correspondence to Jerome Ritz, M.D., Dana-Farber Cancer
Institute, 44 Binney St., Boston, MA 02115.
Receivedfor publication 13 May 1992.
cognate antigen, IL-2 promotes proliferation and differentia-
tion of helper T cells, cytotoxic T cells, and B cells ( 1, 2).
Consequently, IL-2 participates in both cell-mediated immu-
nity and humoral immunity, and is probably necessary for
both primary and secondary adaptive immune responses. IL-2
may also augment innate or "natural" immunity by stimulat-
ing natural killer (NK)' cells (3, 4) and monocytes (5, 6).
Furthermore, IL-2 can induce the classic signs of delayed-type
hypersensitivity even in the absence of specific antigen (7).
Commensurate with the crucial involvement of IL-2 in im-
mune responses, congenital absence of IL-2 production in hu-
mans causes a severe combined immune deficiency with life-
threatening infections ( 8, 9). Replacement therapy with recom-
binant IL-2 (rIL-2) can be effective treatment for this dis-
order (8).
The diverse effects of IL-2 are mediated through specific
cell surface receptors on lymphocytes, monocytes, and other
cell types ( 10). The IL-2R is comprised ofat least two subunits
(10). The intermediate affinity IL-2R is a 70-75-kD protein
that binds IL-2 with an equilibrium Kd of -1 nM; IL-2R p75
can initiate intracellular signal transduction after IL-2 binding
( 11). The low affinity IL-2R (p55 or CD25) is a 55-kD protein
that binds IL-2 with a Kd of - 10 nM. IL-2R p55 has not been
shown to mediate internalization ofIL-2 or signal transduction
by itself. Expressed together on the cell surface, the p75 and
p55 chains can associate noncovalently to form a heterodimer
that binds IL-2 with high affinity (Kd, - 10 pM). Most resting
T cells and B cells express neither IL-2R p75 nor p55 and do
not respond to exogenous IL-2 ( 10 ). However, after activation
by antigen or mitogens, T cells and B cells express high affinity
IL-2R heterodimers and proliferate in an IL-2-dependent fash-
ion (10, 11). By comparison, almost all resting NK cells in
human peripheral blood constitutively express isolated IL-2R
p75 chains ( 12-14). Thus, NK cells can be activated by nano-
molar concentrations ofIL-2 in the absence ofadditional stim-
uli. Since NK cells comprise - 10% of PBL, as many as 109
circulating lymphocytes are potentially immediately respon-
sive to IL-2.
The predominant therapeutic use of IL-2 to date has been
as an immunostimulant in patients with cancer ( 15, 16). Based
on the paradigms of cytotoxic chemotherapy, IL-2 has been
administered in progressively higher doses to define the maxi-
mally tolerated dose ( 17, 18), and bolus intravenous infusions
of 15-150 x 106 U (1-10 mg) of IL-2 have been used in most
subsequent clinical trials ( 15, 16). Approximately 15-20% of
patients with advanced renal cell carcinoma or melanoma dem-
1. Abbreviations used in this paper: ADCC, antibody-dependent cellu-
lar cytotoxicity; E/T, effector to target (ratio); NK, natural killer
(cells); PE, phycoerythrin; rIL-2, recombinant interleukin 2.
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onstrate objective tumor responses after "high dose" IL-2 ther-
apy. Unfortunately, such treatment is associated with life-
threatening toxicities, including severe hypotension, pulmo-
nary edema, renal failure, cardiac arrhythmias, and neurologic
dysfunction ( 19, 20). It is unclear whether beneficial responses
can be induced by lower, more physiologic doses of IL-2 that
would not lead to such severe systemic toxicity.
We recently published the preliminary results of a phase I
trial of rIL-2 given in low doses (0.5-6.0 X 105 U/M2 per d;
3.3-40 ,ug/m2 per d) by continuous intravenous infusion for 3
mo to patients with advanced cancer (21 ). Toxicity was mod-
est and generally did not impair the normal daily activities of
these ambulatory patients. Almost all patients receiving be-
tween 1.5 X 105 U/M2 per d (10 ,g/m2 per d) and 6.0 X 105
U/m2 per d (40 gg/m2 per d) demonstrated significant periph-
eral blood lymphocytosis caused by the selective expansion of
circulating NK cells. In this report, we describe in detail the
immunologic consequences of prolonged low-dose rIL-2 infu-
sion. Our results define a range of IL-2 doses that produces
serum IL-2 concentrations sufficient to saturate high affinity
IL-2 receptors and induces a marked selective expansion of
circulating NK cells.
Methods
Description ofthe clinical study. 21 patients with advanced cancer re-
ceived prolonged continuous intravenous infusions of rIL-2 at doses
that ranged from 0.5 X 105 U/rM2 per d ( 3.3 Ag/m2 per d) to 6.0 X 105
U/M2 per d (40 ,4g/m2 per d) (specific activity 1.5 x 107 U/mg pro-
tein). At least three patients received 2 10 wk of rIL-2 infusion at each
of the four dose levels tested. Recombinant human IL-2 was supplied
by Hoffmann-LaRoche (Nutley, NJ). This clinical trial was carried out
with the approval of the Human Subjects Protection Committee,
Dana-Farber Cancer Institute (Boston, MA). All patients gave in-
formed consent for participation in this study. Patient characteristics
and toxicities have been described elsewhere (21). Blood specimens
were collected at weekly or biweekly intervals in heparinized 60-cm3
syringes, and PBMC were immediately separated by Ficoll-Hypaque
density gradient centrifugation. Cells were washed three times and re-
suspended in RPMI 1640 medium (Gibco Laboratories, Grand Island,
NY) supplemented with 5% human antibody serum for phenotypic
and functional assays. Aliquots of PBMC were also cryopreserved in
liquid nitrogen for later use in proliferation and cytotoxicity assays.
Blood specimens were also obtained periodically for determinations of
complete blood counts, serum chemistries, and serum IL-2 levels.
Analysis ofcellsurface antigens. Single- and two-colorimmunofluo-
rescence analysis was performed using FITC- and phycoerythrin (PE)-
conjugated murine mAb as previously described (22). CD2, CD3,
CD4, CD5, CD8, CD20, CD25, CD56, and anti-IL-2R p75 antibodies
were supplied by Coulter Immunology (Hialeah, FL). FHTC-conju-
gated anti-IL-2Rp75 mAb TU-27 was kindly provided by Dr. Kazuo
Sugamura, Tohoku School of Medicine (Sendai, Japan). CD16 mAb
3G8 was kindly provided by Dr. Jay Unkeless, Mount Sinai School of
Medicine (New York). Flow cytometry was performed on an Epics V
or Epics Elite (Coulter Electronics, Hialeah, FL) and results were dis-
played as single color histograms or as two-color orthographic projec-
tions plotting log green fluorescence versus log red fluorescence. Back-
ground fluorescence was determined by incubating cells with fluoro-
chrome-conjugated murine mAb of irrelevant specificity.
Cytotoxicity assays. NK cytolytic activity was measured using stan-
dard 4-h 5'Cr-release assays as previously described (23). 5,000 5'Cr-la-
beled target cells were added to wells of V-bottom 96-well microtiter
plates, and effector cells were plated in triplicate to yield various effec-
tor to target (E/T) ratios. Patient PBMC were assayed for cytotoxicity
immediately after separation from peripheral blood or after overnight
(18-h) incubation at 37°C in media alone or in media containing
various concentrations ( 10 pM- 10 nM) of rIL-2. Target cells included
K562 (an NK-sensitive human myeloid leukemia cell line), COLO
205 (an NK-resistant human colon adenocarcinoma cell line), and
P815 (an NK-resistant murine mastocytoma cell line). Antibody-de-
pendent cellular cytotoxicity (ADCC) assays were performed against
P815 cells preincubated with either medium alone or with a 1:100
dilution of polyclonal rabbit anti-mouse lymphocyte serum (Accurate
Chemical & Scientific Corp., Westbury, NY) as previously de-
scribed (23).
Proliferation assays. Cryopreserved patient PBMC were thawed,
stained with PE-conjugated CD56 mAb, and sorted into CD56+ and
CD56- subsets by standard methods using flow cytometry. PBMC
from healthy volunteer donors were isolated by Ficoll-Hypaque den-
sity gradient centrifugation, enriched forNK cells by negative selection
using immunomagnetic beads, and sorted into CD56dim and CD56bright
subsets by flow cytometry as previously described (23). Lymphocyte
subsets were plated at 30,000 cells per well in 96-well U-bottom micro-
titer plates and cultured at 37°C; 1 ACi of tritiated thymidine was added
to each well after 4 d. Samples were collected 18 h later using a cell
harvester, and thymidine incorporation was determined using a liquid
scintillation counter as previously described (23).
Measurement of serum IL-2 concentrations. Serum samples were
assayed for IL-2 using an IL-2 enzyme immunoassay kit from Ad-
vanced Magnetics, Inc. (Cambridge, MA). Each sample was assayed in
duplicate (undiluted or diluted 1:2, 1:4, and 1:8) and compared to a
standard curve using homogeneous rIL-2 (Takeda Chemical Indus-
tries, Ltd., Osaka, Japan). The lower limit of detection in this assay is
10 pM.
Results
Changes in lymphocyte subsets during continuous infusion rIL-
2. Phenotypic analyses of T cell, B cell, and NK cell popula-
tions were performed every 7-14 d while patients were receiv-
ing rIL-2. Quantitative changes in circulating NK (CD56+)
cells are summarized in Fig. 1 A. At the lowest dose level, (0.5
x I05 U/iM2 per d or 3.3 Ag/m2 per d), there was no apprecia-
ble change in NK cell number. However, at dose levels of 1.5,
4.5, and 6.0 x 01 U/m2 per d ( 10, 30, and 40 Ag/m2 per d,
respectively), there were consistent increases in the NK cell
population during the course of IL-2 infusion. In the peripheral
blood of three patients who completed 2 10 wk of therapy at
1.5 X 105 U/iM2 per d, the absolute number of total NK cells
increased from a mean of 134/,ul at week 0 to 410/,ul at week
12. In patients who completed 2 10 wk of therapy at 4.5 X I0'
U /m2 per d, the absolute number of total NK cells increased
from a mean of 165/AI at week 0 to 2,425/,l at week 12.
Similarly, at a dose of 6.0 X 105 U/M2 per d, the absolute
number ofNK cells increased from 247/l at week 0 to 1,337/
Iul at week 12. In these patients, the increase in circulating NK
cells occurred gradually throughout the entire period of IL-2
infusion, and there was no evidence to suggest decreased re-
sponsiveness over time. It is also noteworthy that a dose-depen-
dent increase in NK cells was observed in patients who received
1.5 x 105 U/M2 perd or 4.5 x 105 U/M2 perd, while a further
increase in dose to 6.0 x 105 U/iM2 per d did not result in any
additional expansion in the NK cell population. In fact, only a
five to sixfold increase in NK cells was noted at 6.0 x I0 5 U/ m2
per d compared to an average 15-fold increase in patients
treated with 4.5 x 105 U/iM2 per d.
The absolute number of CD3 + T cells remained essentially
the same for all patients at each of the final three dose levels,
with a mean value of 1,170/,l at week 0 and a mean value of
1 ,030/,l at week 12 (Fig. 1 B). Additional studies were per-
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levels. Values were obtained by multiplying the absolute lymphocyte
count by the percent CD5 + cells identified by flow cytometric analy-
sis. Each point represents the mean value for at least three patients
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formed to assess whether T cell activation occurred in vivo
during infusion of low dose rIL-2. Proliferation studies per-
formed in vitro failed to demonstrate any spontaneous prolifer-
ation of patient T cells, yet showed normal responses after in
vitro activation with either PHA or anti-CD2 antibodies (data
not shown). Although no patient exhibited a persistent in-
crease in circulating T cells, transient increases in T cells were
noted in several patients during rIL-2 infusion. For example, at
the final two doses, a transient increase in absolute T cell num-
ber (arbitrarily defined by a twofold increase from pretherapy
value) was noted in four patients, followed by a return to near
baseline values within 14 d. Each episode of T cell increase
occurred within the first 5 wk ofinitiating the infusion, with the
exception of one patient who demonstrated a second increase
during weeks 9 and 10. Phenotypic analyses performed during
these increases did not reveal any selective changes in either
CD4 or CD8 T lymphocyte subsets. Absolute numbers of B
lymphocytes (CD20+ cells) remained relatively unchanged
during the entire period of IL-2 infusion. The mean value for
absolute numbers ofB cells at the three highest dose levels was
901,ul at week 0 and 12O/h1 at week 12. In addition, there were
no significant changes in serum IgG, IgM, or IgA levels either
during or after the continuous in vivo infusion of rIL-2 (data
not shown).
IL-2 induced expansion of CD56bri'gh NK cells. The
CD56b"Ot subset ofNK cells represents only - 10% ofhuman
NK cells and < 1% of all resting human PBL, yet is the only
lymphocyte population that constitutively expresses the high
affinity IL-2R and exhibits a profound proliferative response to
low concentrations of rIL-2 in vitro (24-26). As shown in Fig.
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Figure 2. Expression of
the CD56 antigen by
PBL obtained from an
individual patient at in-
dicated time points be-
fore, during, and after
the continuous infusion
of4.5 x 105 U/m2 per
d of rIL-2. Freshly iso-
lated nonadherent PBL
were stained with PE-
conjugated mAb
NKH I (CD56) and an-
alyzed by flow cytome-
try. Percent CD56+ cells
is indicated in the upper
right. Note the promi-
nent expansion of
CD56bfl60t cells during
the rIL-2 infusion, and
subsequent regression
of the CD56brihlt popu-
lation after discontinua-
tion of IL-2. The last
analysis was performed
after a 2-wk interrup-
tion in IL-2 therapy.
ripheral blood NK cells during IL-2 infusion at doses of 1.5-6.0
X 105 U/M2 per d revealed a gradual increase in the CD56b lgt
population compared to the CD56dim cells. While the
CD56b1Ot cells accounted for < 10% ofCD56+ cells in all pa-
tients before the infusion of rIL-2, this population accounted
for the majority of CD56+ cells after the 12-wk continuous
infusion of rIL-2 at the two highest doses. In some cases, there
was a 2 100-fold increase in the absolute number ofCD56blOlt
cells. The discontinuation of rIL-2 infusion was invariably fol-
lowed by a decrease in the number ofCD56bflsht cells in periph-
eral blood within days to weeks (Fig. 2, A-D).
CD 16 (FcyRIII) is expressed by the majority ofhuman NK
cells and is the receptor that triggers NK cell ADCC (27, 28).
In normal peripheral blood, the CD56bight population ex-
presses little or no CD 16 and mediates ADCC relatively poorly
(25, 29). In patients receiving continuous infusion IL-2, the
expanded CD56b 'lt cells demonstrated little change in CD16
antigen density, and the vast majority coexpresses CD16 (Fig.
3). Nevertheless, a significant fraction ofthe CD56+ cells in all
patients were also CD 16 negative. Additional two-color immu-
nofluorescence analysis demonstrated that the CD56+ cells
consistently lacked CD3, CD4, and CD5, while > 95% ofthese
lymphocytes expressed CD2 and - 40% expressed CD8 (data
not shown).
Expression ofIL-2 receptors on expandedNK cells. During
the course of rIL-2 infusion we also examined expression of
both p55 and p75 subunits ofthe IL-2 receptor byNK cells and
T cells using direct two-color immunofluorescence analysis. As
shown for a representative patient in Fig. 4, few NK cells ex-
pressed IL-2R p55 by flow cytometric analysis either before or
during rIL-2 infusion. In contrast, expression ofIL-2R p75 was
evident on almost all CD56+ cells before treatment, and there
appeared to be an increase in antigen density during the period
ofIL-2 infusion. Simultaneous analysis ofT cells failed to dem-
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Figure 3. Coexpression ofCD56 and CD16 (Fcy RIII) by peripheral blood NK cells in a representative patient receiving continuous IL-2 infusion
of 4.5 x 105 U/M2 per d. Nonadherent PBL obtained at the indicated time points were stained with PE-conjugated anti-CD56 mAb and FITC-
conjugated anti-CD 16 mAb and analyzed by flow cytometry. Note the predominance ofCD16+ CD56dim NK cells prior to therapy and the ex-
pansion of both CDl6+6 CD56bh' and CD16- CD56b'Ot cells during the rIL-2 infusion.
onstrate significant expression of either IL-2R p55 or IL-2R
p75 on CD3+ cells as a result of IL-2 infusion (data not
shown). Furthermore, Northern blot analysis performed on
purified populations ofT cells from selected patients receiving
low dose rIL-2 infusion showed only minimal expression of
IL-2R p75 mRNA when compared with NK cells isolated
under identical conditions, or compared with T cells after CD3
activation (data not shown).
Effects ofrIL-2 infusion on non-MHC-restricted cytotoxic
T lymphocytes. A small subset of resting CD3 + cells expresses
the CD56 antigen at low density; these unique T cells comprise
- 2% of normal PBL (30). CD56+ CD3+ cells exhibit the
morphology of large granular lymphocytes, mediate spontane-
ous non-MHC-restricted cytotoxicity when freshly isolated,
and demonstrate augmented lysis of NK-resistant tumor cell
lines after short-term incubation in nanomolar concentrations
ofrIL-2 (30). While detected in virtually all patients in varying
percentages before the initiation oftherapy, this population did
not expand during continuous low dose rIL-2 infusion. This
can be best appreciated in one patient with an unusually high
percentage of CD56+ CD3+ non-MHC-restricted T cells be-
fore treatment (Fig. 5). The percentage ofCD56+ T cells pro-
gressively diminishes as the absolute number ofCD56+ CD3-
NK cells selectively expands during continuous infusion low
dose rIL-2 therapy. Similar results were obtained with all pa-
tients treated on this study (not shown). Thus CD56+ CD3+
lymphocytes, like conventional CD56- CD3+ T cells, do not
appear to express high affinity IL-2R or to proliferate in vivo in
the presence of low concentrations of IL-2.
Effects ofIL-2 infusion on cytolytic activity ofNK cells. The
cytolytic activity of PBMC against both NK sensitive (K562)
and NK resistant (COLO 205) target cells was examined peri-
odically during the course ofrIL-2 infusion. A gradual increase
in cytotoxicity against K562 target cells was detected during
IL-2 therapy, generally correlating with the degree ofexpansion
ofcirculatingNK cells (21 ). Patients treated at the highest dose
level (6.0 x 105 U/iM2 per d) exhibited low but significant
killing ofCOLO 205 target cells during rIL-2 infusion. NK cells
incubated in vitro with nanomolar concentrations of IL-2 de-
velop non-MHC-restricted cytotoxicity against tumor cell tar-
gets generally resistant to lysis by resting NK cells lymphokine-
activated killer (LAK activity) (31, 32). Further studies were
undertaken to determine whether the cytolytic activity ofNK
cells expanded in vivo by low dose rIL-2 infusion could be
further enhanced by incubation with rIL-2 in vitro. Fig. 6 dem-
onstrates results obtained using PBMC from a representative
patient after 8 wk of continuous rIL-2 infusion at 6.0 x I05
U/M2 perd. PBMC incubated overnight in medium alone dem-
onstrated only minor cytotoxicity against NK-resistant target
cells, and the presence of low concentrations of IL-2 (10 pM)
did not enhance cytotoxicity. Cytotoxicity was enhanced after
incubation of PBMC with 100 pM IL-2, but this was evident
only at the higher effector/target cell ratios. Incubation with
higher concentrations of IL-2 ( 1-10 nM) produced markedly
enhanced killing of the NK-resistant target, even at low effec-
tor/target ratios.
ADCC by PBMC was also tested during the course of rIL-2
infusion. PBMC isolated before low dose rIL-2 infusion failed
to demonstrate any significant lysis ofthe P815 murine masto-
cytoma cell line in the absence (Fig. 7 A) or presence (Fig. 7 B)
ofthe polyclonal rabbit anti-mouse lymphocyte serum; further
incubation with varying concentrations of exogenous rIL-2
also failed to induce killing of P815 target cells. After in vivo
expansion of CD56+ cells by low dose rIL-2 infusion for 6-8
wk, no significant cytotoxicity was seen in the absence of poly-
clonal rabbit anti-mouse lymphocyte serum. Despite further
stimulation with rIL-2 in vitro, minimal cytotoxicity occurred
even at the highest concentration of IL-2 (10 nM) (Fig. 7 C).
After addition of polyclonal rabbit anti-mouse lymphocyte
serum and exogenous IL-2 (Fig. 7 D), however, the expanded
CD56+ cells exhibited a high degree of ADCC. As with NK
activity and lymphokine-activated killer activity, high concen-
trations of IL-2 (1-10 nM) were required to demonstrate en-
hanced ADCC.
Proliferative responses ofNK cells expanded in vivo by rIL-
2 infusion. Since NK cell numbers progressively increased in
patients receiving low dose continuous infusion rIL-2, it
seemed likely that these expanded NK cells would proliferate
vigorously to exogenous IL-2. Surprisingly, CD56+ cells iso-
lated by flow cytometric cell sorting from the blood of patients
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Figure 4. Expression of p55 and p75 IL-2R by peripheral blood CD56+ NK cells from a representative patient before and during (week 5)
continuous rIL-2 infusion of 4.5 x I05 U/rm2 per d. Nonadherent PBL were stained with PE-conjugated anti-CD56 mAb and either FITC-con-
jugated anti-IL-2R p55 (A and B) or FITC-conjugated anti-IL-2R p75 (C and D) and analyzed by flow cytometry. Actual values for percent
double-positive cells is indicated in the upper right quadrant of each histogram.
on low dose IL-2 therapy showed very little proliferation to
exogenous IL-2 in vitro (Table I). These expanded NK cells
demonstrated almost no proliferation to IL-2 in concentrations
of 10 pM (Table I), and anti-IL-2R p55 mAb failed to abro-
gate their proliferation to higher concentrations of IL-2 (not
shown). Although some proliferation was consistently seen
when expanded NK cells were cultured with 1 nM or 10 nM
IL-2, the degree of proliferation was much less than that seen
with CD56b i"'t NK cells freshly isolated from normal donors
(Fig. 8). Indeed, the proliferative response of NK cells ex-
panded in vivo closely resembles that of normal CD56dlm NK
cells.
Serum concentrations ofIL-2 during rIL-2 infusion. Serial
measurements of serum IL-2 concentrations were carried out
in 11 patients while they were receiving continuous infusions
of IL-2. As shown in Fig. 9, IL-2 was undetectable (concentra-
Selective Natural Killer Cell Modulation In Vivo by Low Dose Interleukin 2 127






























Figure 5. Relative decrease in peripheral blood CD56+ CD3+ cytotoxic T cells in a single patient receiving continuous rIL-2 infusion at 4.5 x 105
U/M2 per d. Nonadherent PBL were obtained at the indicated time points during rIL-2 therapy, stained with PE-conjugated anti-CD56 mAb
and FITC-conjugated anti-CD3 mAb, and analyzed by flow cytometry. Despite an unusually high percentage of CD56+ CD3+ cells in the pe-
ripheral blood ofthis patient before IL-2 therapy, this lymphocyte population failed to demonstrate any expansion during prolonged rIL-2 infu-
sion, while CD56+ CD3 - NK cells were markedly increased (lower right quadrant ofeach histogram).
tion < 10 pM) in the serum of patients treated at the first dose
level of0.5 x 105 U/m2 per d. At a dose of 1.5 x 105 U/m2 per
d, the mean serum IL-2 concentration during infusion was
25±25 pM, but one of three patients did not have consistently
detectable levels. At a dose of 4.5 x 105 U/M2 per d, the mean
serum IL-2 concentration during infusion was 77±64 pM. At
the highest dose used, 6.0 x I05 U/iM2 per d, there was greater
variation in serum IL-2 concentration seen between patients.
One patient had a mean concentration of 39±4 pM, a second
patient had a mean concentration of 383±216 pM, and the
third patient treated at this dose had a mean concentration of
776±336 pM. Of these three patients, the one with the lowest
serum IL-2 concentration had the most profound increase in
NK cell number during rIL-2 infusion, while the one with the
highest serum IL-2 concentration showed the least increase in
NK cells.
During the course of this trial, one patient failed to show
any increase in NK cell number as seen in the majority of
patients treated at similar doses. The patient was treated at 1.5
x 105 U/M2 per d, yet had undetectable (< 10 pM) serum
concentrations ofrIL-2 throughout the infusion. This is in con-
trast to the two other patients treated at this dose, who showed
100- Figure 6. Lysis of NK-
> 80 - resistant target cells by
lymphocytes expanded
60 in vivo by rIL-2 infu-
o sion. Nonadherent PBL
Q 40 - /t (64% CD56+ cells)
were isolated from the
20.- ............... , 4blood of a representa-
0 SE tive patient after 8 wk
20 30 40 of rIL-2 infusion at 6.0
E:T ratio X 105 U/m2 per d, cul-
tured for 18 h in either
media alone or media containing 10 pM, 100 pM, 1 nM, or 10 nM
rIL-2 as indicated, and tested for lysis of 5'Cr-labeled COLO 205 tar-
get cells at various E/T ratios. Results represent the mean percent
lysis for triplicate samples. COLO target cells: --- ---, media; 0
-, 10 pM; -, 100 pM; -o -, 1 nM; , 10 nM.
measurable serum levels of rIL-2 and had more than a seven-
fold increase in the absolute NK cell number during the 3 mo
of rIL-2 therapy. A second patient demonstrated increases in
NK cell number during the infusion, but at a rate which was
significantly slower than the majority of patients. This patient
was treated at the highest dose level (6.0 x 105 U/M2 per d),
and had serum rIL-2 concentrations that were the highest in
the study, ranging between 419 and 1,230 pM. In addition, this
patient uniquely exhibited a profound increase in both neutro-
phil and eosinophil counts, as well as a significant decrease in
platelet count, suggesting that additional activation via the IL-
2R p75 may have resulted in a multitude of stimulatory and
inhibitory hematologic effects, possibly through the release of
additional cytokines (33-35).
The relationship between the IL-2 dose administered,
serum IL-2 levels attained, and the calculated percentage of
IL-2 receptor occupancy are shown in Table II. Since the Kd for
the three classes of IL-2 binding sites differ by three orders of
magnitude, there is a marked difference in the proportion of
receptors occupied at each IL-2 dose level. Thus, the high affin-
ity IL-2 receptor (Kd, 10 pM) is > 90% saturated when the IL-2
concentration is 100 pM, while < 10% of the intermediate af-
finity receptors are occupied at this concentration. However,
26% of the intermediate affinity receptors are occupied at a
serum IL-2 level of 345 pM.
Discussion
We have investigated the immunologic consequences ofmain-
taining near-physiologic serum concentrations of IL-2 for ex-
tended periods by prolonged intravenous infusions ofthe cyto-
kine. The doses of rIL-2 administered could produce serum
IL-2 concentrations ( 10-100 pM) that selectively saturate high
affinity IL-2R heterodimers, as well as concentrations ( 1-
nM) that can engage isolated intermediate affinity IL-2R p75.
Such therapy induced a profound and selective expansion of
NK cells without any substantial change in the absolute num-
ber of T cells, B cells, or monocytes. A clear dose-response
effect was seen between 1.5 x 105 U/M2 per d and 4.5 x 105
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Figure 7. ADCC mediated by lymphocytes expanded
in vivo by rIL-2 infusion. PBL obtained from three
-0 patients before (A and B) or after (C and D) IL-2
therapy were cultured for 18 h in media alone or me-
dia containing IL-2 at the indicated concentrations
A4 and then tested for cytotoxicity against P815 cells
preincubated with media alone (A and C) or polyclo-
nal rabbit anti-mouse lymphocyte serum reactive with
P815 (B and D). PBL before therapy contained 14%,
13%, or 26% CD56+ cells, respectively. PBL obtained
after 6-8 wk of rIL-2 infusion at 6.0 x I0 U/im2 per
d contained 50%, 77%, or 79% CD56+ cells. Each
1 0 point represents the mean value of percent lysis by
PBL from the three patients.
U/m2 per d, which resulted in serum IL-2 concentrations of
- 25 pM and 77 pM, respectively. Increasing the IL-2 dose
from 4.5 x 10 5 U/rm2 per d to a slightly higher dose of6.0 x I05
U/M2 per d did not result in further NK cell expansion. Serum
IL-2 levels at this highest dose were variable, which may in part
reflect poor renal excretion of IL-2 as a consequence of pre-
vious chemotherapy-induced nephrotoxicity. In two of three
patients, this dose produced serum IL-2 levels sufficient to en-
gage intermediate affinity IL-2R (Kd, 1 nM). Commensurate
with this, the circulating NK cells from these patients demon-
strated higher levels of NK cytotoxicity compared with NK
cells from patients receiving the lower doses ofIL-2. The obser-
vation that absolute peripheral blood NK cell numbers were
actually lower after continuous infusion of6.0 x I05 U/rm2 per
d ofrIL-2 than after infusion of4.5 x l0 U/M2 per d is intrigu-
ing. Activation ofNK cells through IL-2R p75 causes the upreg-
Table I. Proliferation ofNK Cells Expanded In Vivo by rIL-2
Infusion
Proliferation (cpm) in the presence ofIL-2 concentration of:
Week
Patient on IL-2 None 10 pM 100 pM 1 nM 10 nM
1 6 231 149 448 4,351 N.D.
2 12 238 230 403 8,391 13,102
3 11 284 467 485 2,834 2,948
4 12 580 295 3,528 10,680 4,664
Total CD56+ NK cells from the peripheral blood of patients receiving
rIL-2 infusions of 6 x l0 U/M2 per d for 6-12 wk were cultured in
vitro with medium alone or medium containing various concentra-
tions of IL-2 as indicated. Tritiated thymidine incorporation was
determined as described in Methods. Results are mean cpm from
triplicate wells. N.D., not done.
ulation of certain NK cell adhesion molecules (22), and thus
the higher serum IL-2 concentrations produced by the 6.0
x 105 U/rm2 per d dose might have induced the extravasation
ofexpanded NK cells into tissues. Alternatively, secondary cy-
tokines may have been produced by NK cells or monocytes
stimulated through IL-2R p75, resulting in both systemic toxic-
ity and an inhibitory effect on NK cell expansion. Of note, the
number of circulating cytotoxic effectors induced by chronic
low dose IL-2 therapy in some instances equaled the number of
effectors that can be generated ex vivo using high dose IL-2
( 15 ). Furthermore, this expanded NK population was evident
for months and showed no sign of diminution throughout the
course of IL-2 infusion. Despite the dramatic increase in NK
cell numbers, NK cytotoxicity against tumor targets was only
slightly enhanced at dose levels of 1.5 x 105 U/rm2 per d and
4.5 x 105 U/rm2 per d. Thus, prolonged low-dose IL-2 infusion
50X00 Figure 8. IL-2-induced
f 40000 proliferation of normal
CD56""' NK cells,
o 30 _ normal CD56"m NK
cells, and NK cells ex-
panded in vivo during
o10000- _ rIL-2 infusions. Sorted
0 _ _ o _ CD5614"g" (A) and
A B C CD56dIm (B) NK cell
subsets from healthy
donors or sorted total CD56' NK cells (C) from patients receiving
rIL-2 infusions at 6.0 x iOs U/M2 per d for 6-12 wk were isolated
by flow cytometry and cultured for 5 d in medium containing 1 nM
IL-2. Tritiated thymidine incorporation was determined as described
in Methods. Data represent mean±SD ofcpm forNK cells derived
from four normal donors (A and B) or four IL-2 patients (C). Back-
ground cpm in the presence of medium alone (278±35 for A,
322±119 for B, and 245±27 for C) have been subtracted.
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Figure 9. Serum rIL-2 concentrations in 11 patients receiving contin-
uous intravenous infusions of rIL-2 for 90 d. Patients 1 and 2 re-
ceived 0.5 x 10' U/rm2 per d; patients 3, 4, and 5 received 1.5 x 10'
U/m' per d; patients 6, 7, and 8 received 4.5 x 105 U/M2 per d; and
patients 9, 10, and 11 received 6.0 x 105 U/M2 per d of rIL-2. Each
point represents a separate measurement. Serum levels were drawn
randomly throughout the infusions. IL-2 was not detectable in the
serum of any patient before the initiation of rIL-2 therapy.
can produce prominent NK cell expansion without activation
of substantial NK cytolytic activity. However, brief in vitro
incubation of expanded NK cells with concentrations of IL-2
sufficient to bind IL-2R p75 resulted in marked cytotoxicity
against NK-sensitive, NK-resistant, and antibody-coated target
cells. This is consistent with the expression of isolated interme-
diate affinity p75 detected on expanded NK cells by flow cy-
tometry. The ability to expand the NK population at low, non-
toxic doses of rIL-2 and then to activate highly specific anti-
body-directed target cell killing using a higher dose of rIL-2
(Fig. 7) suggests future strategies for immunotherapy.
Despite inducing up to 15-fold increases in the absolute
number of circulating NK cells, low dose continuous infusion
IL-2 caused no significant increase in B cells, CD56- CD3+
conventional T cells, or CD56+ CD3+ MHC-unrestricted T
cells in most patients. The selective NK cell expansion reported
here was expected based on the known distribution ofIL-2R on
normal resting human lymphocytes (24). The vast majority of
T cells and B cells express neither intermediate nor high affinity
IL-2R binding sites until activated by antigen, and these lym-
phocytes are therefore largely unresponsive to exogenous rIL-2
Table II. Relationship between IL-2 Dose, Serum IL-2
Concentration, and IL-2R Occupancy
Percent receptor occupancy
Serum
IL-2 dose (IL-2) High Intermediate Low
Ag/m2 per d pM
3.3 <10 - -
10 25 71 2 <1
30 77 88 7 1
40 345 97 26 3
Calculation based on the Kd of each class of receptor: high affinity, Kd
= 10 pM; intermediate affinity, Kd = 1 nM; low affinity, Kd = 10
nM (1 1).
(IL-2)
Percent RC. = x 100, where Ro. is the receptor occupancy.
( 10, 24). In contrast, - 90% ofNK cells express IL-2R p75 in
the absence of IL-2R p55 and demonstrate enhanced cytolytic
activity in response to concentrations (- 1-10 nM) of rIL-2
that half-saturate intermediate affinity IL-2R. A novel subset
ofNK cells, identified by high density expression of the CD56
antigen, appears to express constitutively high affinity IL-2R
p55 / 75 heterodimers, as well as an excess of isolated interme-
diate affinity IL-2R p75. These CD56" t' NK cells can prolifer-
ate to concentrations (- 10-100 pM) of rIL-2 that saturate
only high affinity IL-2R. In contrast, although briefincreases in
T cell number occurred in several patients during the infusion
of rIL-2, the number of T cells generally returned to baseline
levels within 2-3 wk; a cumulative increase in T cell number
was not observed. Transient proliferation ofT cells during rIL-
2 infusion is not unexpected, since T cells are presumably acti-
vated intermittently in vivo after encountering cognate anti-
gen. After antigen stimulation, T cells express high affinity IL-
2R p55/p75 heterodimers and proliferate in the presence of
picomolar concentrations of IL-2. However, high affinity IL-
2R are downregulated on T cells 10-14 d after activation ( 10),
and thus T cell expansion would not be expected to persist
despite the continued presence of exogenous rIL-2. In contrast
to activated T cells, activated NK cells do not appear to pro-
duce significant amounts of IL-2 (27, 36); thus NK cells are
probably incapable of autocrine stimulation through the IL-2
pathway. However, the expandedNK cells in our patients dem-
onstrate stable or even enhanced surface staining with IL-2R
p75 mAb, and their cytolytic activity can be augmented by
nanomolar concentrations of IL-2 in vitro. Thus, we have no
evidence to suggest that these NK cells downregulate IL-2R
p75 after prolonged exposure to exogenous IL-2.
Most previous cancer immunotherapy trials have involved
very high doses of rIL-2 (- 15-150 X 106 U or 1-10 mg)
administered intravenously over several days or intermittently
over several weeks ( 15, 16). The immunologic and clinical
effects of high dose IL-2 therapy contrast markedly with those
seen in our trial. High dose therapy commonly causes a pro-
found lymphopenia followed by rebound lymphocytosis com-
prised of both T cells and NK cells ( 17, 37, 38). Most human
NK cells (12-14) and monocytes (6) constitutively express
isolated IL-2R p75 chains, and nanomolar concentrations of
IL-2 can induce the secretion of several cytokines by these cells
(6, 28, 36, 39). The T cell activation detected in patients re-
ceiving high dose IL-2 is likely caused by secondary cytokines
derived from activated NK cells and monocytes, rather than
directly caused by rIL-2 itself. Indeed, PBMC from patients
receiving high dose IL-2 infusions demonstrate enhanced ex-
pression of mRNA for several cytokines, including IL- 1, IL-5,
IL-6, INF-'y and tumor necrosis factor, and elevated blood lev-
els of these cytokines can be detected in some patients after
IL-2 therapy (33-35). Furthermore, such cytokines may con-
tribute to the severe toxicities ofhigh dose IL-2 therapy, includ-
ing hypotension (40) and the vascular leak syndrome (41 ). In
this regard, the selective NK cell modulation and mild toxicity
that we describe after infusion of low dose IL-2 may delineate
the direct effects of IL-2 as opposed to the confounding effects
of secondary cytokines.
Although selective NK cell expansion was expected in this
trial, the physiologic basis for the markedly increased NK cell
number during low dose rIL-2 infusion is not entirely clear. A
preferential expansion of CD56 '"t NK cells was seen in this
study, as well as other IL-2 trials (42, 43). Since freshly isolated
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CD56b"ht NK cells from normal donors express high affinity
IL-2R and proliferate vigorously to low concentrations of IL-2
in vitro, we initially speculated that CD56b'60t circulating NK
cells also selectively proliferated in vivo during IL-2 administra-
tion. However, several observations argue against this hypothe-
sis. CD56bfl"t NK cells in the peripheral blood of healthy per-
sons express little or no surface CD16, while the expanded
CD56b'r*t NK cells from our IL-2 patients are largely
CD16-positive. Furthermore, CD56bflht NK cells from normal
persons express functional high affinity IL-2R, whereas most
expanded CD56bfght NK cells appear to lack high affinity IL-
2R, both by flow cytometric analysis and by in vitro functional
studies using various concentrations of IL-2. Finally,
CD5 b6lrht NK cells from normal persons proliferate vigorously
to low concentrations of exogenous IL-2 in vitro, while NK
cells expanded in vivo demonstrate very little proliferation
even in response to nanomolar concentrations of IL-2.
It is possible that both the CD56b l't and CD56dim NK cells
that accumulate in the peripheral blood of patients receiving
prolonged infusions of low dose IL-2 arise from immature NK
cell progenitors that can proliferate to low concentrations of
IL-2. The regulation of human NK cell differentiation remains
poorly understood. The earliest NK cell progenitors are almost
certainly generated in the bone marrow, but it is uncertain
whether these progenitors differentiate into fully mature effec-
tor cells in the marrow, or whether NK precursors leave the
marrow and undergo differentiation elsewhere (27, 28). How-
ever, human and animal data indicate that immature NK cell
progenitors can be stimulated with exogenous IL-2 to produce
mature NK cells (44-47). Thus, the expanded NK cells in
patients receiving prolonged infusions of low dose IL-2 could
reflect proliferation of both mature peripheral blood CD56b'rt
NK cells and immature NK cell precursors possessing high
affinity IL-2R. Of note, NK cells in these patients progressively
expanded during continuous rIL-2 infusion and subsequently
decreased in number after discontinuation of IL-2 treatment.
Furthermore, reinstitution of IL-2 therapy resulted in recur-
rent NK cell expansion. Thus, the NK cell subset of lympho-
cytes appears to respond to IL-2 in vivo in a manner similar to
the response of certain myeloid cell subsets to hematopoietic
growth factors, such as erythropoeitin or granulocyte colony-
stimulating factor (48). Extending this speculation further,
NK cell production under physiologic conditions might also be
regulated in a fashion more analogous to myeloid cells than to
T and B lymphocytes. Monocytes, granulocytes, and erythro-
cytes are terminally differentiated cells, so a need for increased
numbers of mature myeloid cells is met by increased marrow
production of these cells. In contrast, adaptive immune re-
sponses require the clonal expansion of specific T cells and B
cells, and these lymphocytes proliferate extensively after acti-
vation via their antigen-specific, clonotypic receptors. There is
currently little evidence to suggest that NK cells have clonally
distributed, highly variable receptors (27, 28), so that there is
no obvious advantage to expanding individual clones of ma-
ture NK cells. Therefore, the demand for increased numbers of
NK cells could be met by increasing marrow production from
immature progenitors. This might also explain the apparently
limited proliferative potential of the vast majority of mature
peripheral blood NK cells (29, 36).
Our results indicate that small subpopulations of lympho-
cytes can be selectively and profoundly expanded by prolonged
infusion of low dose rIL-2. This study strongly suggests that T
cells express functional high affinity IL-2R for only a limited
time after antigen activation, while NK cells can respond to
IL-2 without known previous antigen activation and for an
apparently unlimited period of time. Attempts must now be
made to identify patients who might benefit from the expan-
sion of these cytotoxic lymphocytes. For example, patients
with certain hematologic malignancies have a high risk ofrecur-
rent disease despite myeloablative chemoradiotherapy and
bone marrow transplantation. Recent studies have shown that
prolonged low dose rIL-2 therapy can be well tolerated after
either autologous or T cell-depleted allogeneic bone marrow
transplantation (49). Intermittent infusions of higher doses of
IL-2 might also be administered to activate expanded NK cells
via IL-2R p75, in hopes of improving the antitumor activity of
these cells. Furthermore, this approach could be combined
with serotherapy using mAb reactive with tumor cells or vi-
ruses, since most ofthe expanded NK cells express the FcyRIII
(CD16) and can mediate ADCC. Clinical trials to evaluate
these approaches are currently underway. The design of our
IL-2 regimen was based on the pharmacokinetics of IL-2, the
binding affinities of the IL-2R, and the known distribution of
IL-2R on lymphocyte subsets. Further rational clinical trials
with IL-2 and other cytokines could be undertaken using fun-
damental principles of immunology and endocrinology rather
than the paradigms of cytotoxic chemotherapy.
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